Releuko — Point32Health

Glycogen Storage Disease Type 1 with documented low neutrophil count

Preferred products

For prophylaxis of chemotherapy-induced neutropenia: Documentation of solid tumor or non-myeloid malignancy in a patient receiving myelosuppressive chemotherapy AND one of the following:
• Chemotherapy regimen associated with a high risk (>20%) of febrile neutropenia based on NCCN guidelines
• Chemotherapy regimen with intermediate risk (10–20%) of febrile neutropenia AND patient has ≥1 risk factor: age ≥65 years, active infection/open wound/recent surgery, advanced disease (stage 2 or higher or bone marrow involvement), prior chemotherapy or radiation therapy, pre-existing neutropenia, poor ECOG performance status (2–5) or poor nutritional status, comorbidities (cardiovascular, renal [CrCl <50], or hepatic [bilirubin >2.0], HIV), difficulty recognizing or managing fever, or chronic immunosuppression post-transplant
• Patient receiving dose-dense myelosuppressive chemotherapy
• Patient has experienced neutropenic complication (febrile neutropenia or dose-limiting neutropenia) from prior cycle of same chemotherapy
OR diagnosis of acute myeloid leukemia scheduled for induction or consolidation chemotherapy
OR diagnosis of non-myeloid malignancy receiving myeloablative chemotherapy followed by bone marrow transplantation
Other requested use is for one of the specified conditions in indications list above
In addition, documented previous failure, contraindication, or clinical inappropriateness with Zarxio

6 months